NCT05643118View on ClinicalTrials.gov

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC

OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)

Clear colorless solution dissolved in 1X PBS and injected intravitreally

Trial Locations (5)

12180

ACTIVE_NOT_RECRUITING

Ophthalmic Consultants of the Capital Region, Troy

60452

RECRUITING

University Retina, Oak Forest

63128

RECRUITING

The Retina Institute, St Louis

77401

ACTIVE_NOT_RECRUITING

Texas Retina Consultants, Bellaire

93434

RECRUITING

California Retina Consultants, Santa Maria

Sponsors
All Listed Sponsors
collaborator

Trial Runners, LLC

OTHER

lead

Olix Pharmaceuticals, Inc.

INDUSTRY

NCT05643118 - Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter